Interestingly, in many studies, no difference was found in EBV viral loads between the MS and control groups [28,45], indicating that although MS patients are able to efficiently control EBV infection, at least systemically, their CD4+ as well as their CD8+ EBV-specific T cell responses are dysregulated and might rather promote disease pathology. The gene discussed is CD4; the disease is myeloid sarcoma.